Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 20;384(20):1959-1961.
doi: 10.1056/NEJMc2102051. Epub 2021 Mar 23.

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine

Todd Bradley  1 , Elin Grundberg  1 , Rangaraj Selvarangan  1 , Cas LeMaster  1 , Elizabeth Fraley  1 , Dithi Banerjee  1 , Bradley Belden  1 , Daniel Louiselle  1 , Nick Nolte  1 , Rebecca Biswell  1 , Tomi Pastinen  1 , Angela Myers  1 , Jennifer Schuster  1
Affiliations

Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine

Todd Bradley et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Antibody Response to SARS-CoV-2 mRNA Vaccine.
Panel A shows a multiplex bead-based antibody-binding assay that measures the IgG antibody response to four SARS-CoV-2 viral antigens (spike protein subunits S1 and S2, spike receptor-binding domain, and nucleocapsid protein). The median fluorescence intensity (MFI) is shown; background subtraction has been used to remove nonspecific signal. Participants designated as “undiagnosed” were those in the group with no history of SARS-CoV-2 infection who had antibody levels that matched those of participants with recent infection. The dashed line indicates a threshold determined by the sum of the mean and standard deviation for the negative control (i.e., beads without antigen). Panel B shows the results of a neutralization antibody proxy assay that determines the level of antibodies that block binding of the spike protein receptor-binding domain to the human host receptor angiotensin-converting enzyme 2 (ACE2), expressed as the percentage of binding that was blocked relative to a control with no plasma (representing maximum binding). The assay threshold for positivity was 30%. In both panels, each point represents a participant at baseline before receiving the vaccine or 3 weeks after receiving the first dose of vaccine and bars represent the group median. The numbers of participants in each group are shown below the graphs.
See this image and copyright information in PMC

References

    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020;384:403-416. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615. - PMC - PubMed
    1. Lumley SF, O’Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 2020;384:533-540. - PMC - PubMed